Pinned post
Latest posts 5
ohhhh - here's my 2 cents then...
My prediction, is that adequately powered studies will show the benefit of Lp(a) reduction.
This is based on underdstanding the work that has taken place so far, which Dr Mandrola seems to have missed.
My prediction, is that adequately powered studies will show the benefit of Lp(a) reduction.
This is based on underdstanding the work that has taken place so far, which Dr Mandrola seems to have missed.
Good question and interesting paper. 👇🏻View quoted post on X
My 2 cents, Lp (a) is a marker more than a causal agent. I predict w low levels of conviction that Lp (a) lowering trials will be meh
Use #whycmr - it will magically become lower!
The highest I have ever seen !
#echofirst #CardioTwitter
@DrRajeshG1 @iamritu @argulian @alex1708ander @dr_benoy_n_shah @drjasondungu @KemalogluOz @echo_batman @pattypellikkaView quoted post on X
Not a CMR #whycmr study - but important for awareness- yes statins increase Lp(a) a bit but despite this have a HUGE benefit for preventing cardiac disease
In the EPIC-Norfolk study (EHJ 2025, doi.org/10.1093/eurhea…), statin-induced Lp(a) rise (5–20%) increases CV risk by ~1–5% (absolute risk +0.2–1% over 20y).View quoted post on X
Yet, high-intensity statins reduce LDL-C by 50%, cutting CV risk by ~40–50% (absolute risk –15–20% over 20y).
Conclusion: LDL-C lowering >> Lp(a) rise.
